169 related articles for article (PubMed ID: 32250566)
1. Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.
Yellepeddi VK; Baker OJ
Clin Exp Dent Res; 2020 Apr; 6(2):225-235. PubMed ID: 32250566
[TBL] [Abstract][Full Text] [Related]
2. Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.
Yellepeddi VK; Parashar K; Dean SM; Watt KM; Constance JE; Baker OJ
Clin Transl Sci; 2021 Mar; 14(2):683-691. PubMed ID: 33202089
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.
Dean S; Wang CS; Nam K; Maruyama CL; Trump BG; Baker OJ
Rheumatology (Oxford); 2019 Jul; 58(7):1285-1292. PubMed ID: 30877775
[TBL] [Abstract][Full Text] [Related]
4. AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Wang CS; Maruyama CL; Easley JT; Trump BG; Baker OJ
Sci Rep; 2017 Mar; 7():45525. PubMed ID: 28361884
[TBL] [Abstract][Full Text] [Related]
5. Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model.
Parashar K; Schulte F; Hardt M; Baker OJ
FASEB J; 2020 Jun; 34(6):7733-7744. PubMed ID: 32277856
[TBL] [Abstract][Full Text] [Related]
6. AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.
Easley JT; Maruyama CL; Wang CS; Baker OJ
Physiol Rep; 2016 Oct; 4(19):. PubMed ID: 27694530
[TBL] [Abstract][Full Text] [Related]
7. Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.
Easley JT; Nelson JW; Mellas RE; Sommakia S; Wu C; Trump B; Baker OJ
J Rheum Dis Treat; 2015; 1(4):. PubMed ID: 27110599
[TBL] [Abstract][Full Text] [Related]
8. Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.
Dos Santos HT; Nam K; Gil D; Yellepeddi V; Baker OJ
Front Immunol; 2022; 13():1094278. PubMed ID: 36713415
[TBL] [Abstract][Full Text] [Related]
9. ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.
Nelson JW; Leigh NJ; Mellas RE; McCall AD; Aguirre A; Baker OJ
Am J Physiol Cell Physiol; 2014 Jan; 306(2):C178-85. PubMed ID: 24259417
[TBL] [Abstract][Full Text] [Related]
10. Expression of resolvin D1 biosynthetic pathways in salivary epithelium.
Leigh NJ; Nelson JW; Mellas RE; Aguirre A; Baker OJ
J Dent Res; 2014 Mar; 93(3):300-5. PubMed ID: 24389810
[TBL] [Abstract][Full Text] [Related]
11. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.
Kim JW; Kim SM; Park JS; Hwang SH; Choi J; Jung KA; Ryu JG; Lee SY; Kwok SK; Cho ML; Park SH
Arthritis Res Ther; 2019 Jun; 21(1):136. PubMed ID: 31164166
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome.
Wieczorek G; Bigaud M; Pfister S; Ceci M; McMichael K; Afatsawo C; Hamburger M; Texier C; Henry M; Cojean C; Erard M; Mamber N; Rush JS
Ann Rheum Dis; 2019 Jul; 78(7):974-978. PubMed ID: 30902822
[TBL] [Abstract][Full Text] [Related]
13. Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.
Odusanwo O; Chinthamani S; McCall A; Duffey ME; Baker OJ
Am J Physiol Cell Physiol; 2012 May; 302(9):C1331-45. PubMed ID: 22237406
[TBL] [Abstract][Full Text] [Related]
14. Assessment of bromhexine as a treatment regimen in Sjögren's syndrome-like disease in the NOD (non-obese diabetic) mouse.
Nanni JM; Nguyen KH; Alford CE; Robinson CP; Stewart CM; Maeda N; Humphreys-Beher MG
Clin Exp Rheumatol; 1997; 15(5):515-21. PubMed ID: 9307859
[TBL] [Abstract][Full Text] [Related]
15. Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.
Dos Santos HT; Nam K; Maslow F; Trump B; Baker OJ
Ann Diagn Pathol; 2022 Feb; 56():151865. PubMed ID: 34847389
[TBL] [Abstract][Full Text] [Related]
16. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
17. Metabolic abnormalities exacerbate Sjögren's syndrome by and is associated with increased the population of interleukin-17-producing cells in NOD/ShiLtJ mice.
Hwang SH; Park JS; Yang S; Jung KA; Choi J; Kwok SK; Park SH; Cho ML
J Transl Med; 2020 May; 18(1):186. PubMed ID: 32370746
[TBL] [Abstract][Full Text] [Related]
18. Zonula occludens-1, occludin and E-cadherin expression and organization in salivary glands with Sjögren's syndrome.
Mellas RE; Leigh NJ; Nelson JW; McCall AD; Baker OJ
J Histochem Cytochem; 2015 Jan; 63(1):45-56. PubMed ID: 25248927
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-21-mediated suppression of the Pax3-Id3 pathway exacerbates the development of Sjögren's syndrome via follicular helper T cells.
Park JS; Kim SM; Choi J; Jung KA; Hwang SH; Yang S; Kwok SK; Cho ML; Park SH
Cytokine; 2020 Jan; 125():154834. PubMed ID: 31491724
[TBL] [Abstract][Full Text] [Related]
20. Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjögren's syndrome.
Wen J; Zhu F; Yu X; Xie H; Li C
BMC Immunol; 2022 Oct; 23(1):49. PubMed ID: 36244973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
